VEGFA and neoplasm: Bevacizumab (Avastin), a monoclonal antibody targeting VEGFA, prevents VEGFA binding to VEGFR1/2, thereby suppressing angiogenesis and tumor growth (Figure 2C) [87,143,144,146].